Cystatin forms a Tetramer through Structural Rearrangement of Domain-swapped Dimers prior to Amyloidogenesis

Journal of Molecular Biology

Volumn 336, Issue 1, 2004, Pages 165-178

  Sanders, Anna ^a   Jeremy Craven, C ^a   Higgins, Lee D ^a   Giannini, Silva ^a   Conroy, Matthew J ^a   Hounslow, Andrea M ^a   Waltho, Jonathan P ^a   Staniforth, Rosemary A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Amyloid intermediate; CAA; Cystatin; Dimer; Domain swapping

Indexed keywords

8 ANILINO 1 NAPHTHALENESULFONIC ACID; AMYLOID; CYSTATIN; DIMER; MONOMER; TETRAMER;

ARTICLE; CHICKEN; CIRCULAR DICHROISM; DIMERIZATION; FLUORESCENCE; MOLECULAR DYNAMICS; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; TEMPERATURE;

GALLUS GALLUS;

EID: 0345869697     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2003.12.011     Document Type: Article

References (78)

1. Glenner G.G. Amyloid deposits and amyloidosis. New Engl. J. Med. 302:1980;1283-1292.
2. Prusiner S.B. Molecular-biology of prion diseases. Science. 252:1991;1515-1522.
3. Tan S.Y., Pepys M.B. Amyloidosis. Histopathology. 25:1994;403-414.
4. Koo E.H., Lansbury P.T., Kelly J.W. Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc. Natl Acad. Sci. USA. 96:1999;9989-9990.
5. Rochet J.C., Lansbury P.T. Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10:2000;60-68.
6. Sipe J.D., Cohen A.S. History of the amyloid fibril. J. Struct. Biol. 130:2000;88-98.
7. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 24:2001;519-550.
8. Blake C., Serpell L. Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous beta-sheet helix. Structure. 4:1996;989-998.
9. Sunde M., Serpell L.C., Bartlam M., Fraser P.E., Pepys M.B., Blake C.C.F. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol. 273:1997;729-739.
10. Jimenez J.L., Guijarro J.L., Orlova E., Zurdo J., Dobson C.M., Sunde M., Saibil H.R. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 18:1999;815-821.
11. Jimenez J.L., Nettleton E.J., Bouchard M., Robinson C.V., Dobson C.M., Saibil H.R. The protofilament structure of insulin amyloid fibrils. Proc. Natl Acad. Sci. USA. 99:2002;9196-9201.
12. Serpell L.C., Smith J.M. Direct visualization of the beta-sheet structure of synthetic Alzheimer's amyloid. J. Mol. Biol. 299:2000;225-231.
13. Balbach J.J., Petkova A.T., Oyler N.A., Antzutkin O.N., Gordon D.J., Meredith S.C., Tycko R. Supramolecular structure in full-length Alzheimer's beta-amyloid fibrils: evidence for a parallel beta-sheet organization from solid-state nuclear magnetic resonance. Biophys. J. 83:2002;1205-1216.
14. Wetzel R. Ideas for amyloid fibril structure. Structure. 10:2002;1031-1036.
15. Colon W., Kelly J.W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry. 31:1992;8654-8660.
16. Huang T.H.J., Yang D.S., Fraser P.E., Chakrabartty A. Alternate aggregation pathways of the Alzheimer beta-amyloid peptide - an in vitro model of preamyloid. J. Biol. Chem. 275:2000;36436-36440.
17. Kad N.M., Thomson N.H., Smith D.P., Smith D.A., Radford S.E. beta(2)-microglobulin and its deamidated variant, N17D form amyloid fibrils with a range of morphologies in vitro. J. Mol. Biol. 313:2001;559-571.
18. Guijarro J.I., Sunde M., Jones J.A., Campbell I.D., Dobson C.M. Amyloid fibril formation by an SH3 domain. Proc. Natl Acad. Sci. USA. 95:1998;4224-4228.
19. Chiti F., Webster P., Taddei N., Clark A., Stefani M., Ramponi G., Dobson C.M. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl Acad. Sci. USA. 96:1999;3590-3594.
20. Morozova-Roche L.A., Zurdo J., Spencer A., Noppe W., Receveur V., Archer D.B., et al. Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants. J. Struct. Biol. 130:2000;339-351.
21. Modler A.J., Gast K., Lutsch G., Damaschun G. Assembly of amyloid protofibrils via critical oligomers - a novel pathway of amyloid formation. J. Mol. Biol. 325:2003;135-148.
22. Griffith J.S. Self-replication and Scrapie. Nature. 215:1967;1043-1044.
23. Prusiner S.B. Novel proteinaceous infectious particles cause scrapie. Science. 216:1982;136-144.
24. Jarrett J.T., Lansbury P.T. Seeding one-dimensional crystallization of amyloid - a pathogenic mechanism in Alzheimer's disease and scrapie. Cell. 73:1993;1055-1058.
25. Serio T.R., Cashikar A.G., Kowal A.S., Sawicki G.J., Moslehi J.J., Serpell L., et al. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science. 289:2000;1317-1321.
26. Kelly J.W. Mechanisms of amyloidogenesis. Nature Struct. Biol. 7:2000;824-826.
27. Nielsen L., Khurana R., Coats A., Frokjaer S., Brange J., Vyas S., et al. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry. 40:2001;6036-6046.
28. Chiti F., Taddei N., Baroni F., Capanni C., Stefani M., Ramponi G., Dobson C.M. Kinetic partitioning of protein folding and aggregation. Nature Struct. Biol. 9:2002;137-143.
29. Lai Z.H., Colon W., Kelly J.W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry. 35:1996;6470-6482.
30. Booth D.R., Sunde M., Bellotti V., Robinson C.V., Hutchinson W.L., Fraser P.E., et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature. 385:1997;787-793.
31. Kelly J.W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 8:1998;101-106.
32. Jackson G.S., Hosszu L.L.P., Power A., Hill A.F., Kenney J., Saibil H., et al. Reversible conversion of monomeric human prion protein between native and fibrillogenic conformations. Science. 283:1999;1935-1937.
33. McParland V.J., Kad N.M., Kalverda A.P., Brown A., Kirwin-Jones P., Hunter M.G., et al. Partially unfolded states of beta(2)-microglobulin and amyloid formation in vitro. Biochemistry. 39:2000;8735-8746.
34. Kirkitadze M.D., Condron M.M., Teplow D.B. Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. J. Mol. Biol. 312:2001;1103-1119.
35. Abrahamson M., Grubb A. Increased body temperature accelerates aggregation of the Leu-68→Gln mutant cystatin C, the amyloid forming protein in hereditary cystatin C amyloid Angiopathy. Proc. Natl Acad. Sci. USA. 91:1994;1416-1420.
36. Gerhartz B., Ekiel I., Abrahamson M. Two stable unfolding intermediates of the disease-causing L68Q variant of human cystatin C. Biochemistry. 37:1998;17309-17317.
37. Staniforth R.A., Giannini S., Higgins L.D., Conroy M.J., Hounslow A.M., Jerala R., et al. Three-dimensional domain swapping in the folded and molten-globule states of cystatins, an amyloid-forming structural superfamily. EMBO J. 20:2001;4774-4781.
38. Barrett A.J. The cystatins - a new class of peptidase inhibitors. Trends Biochem. Sci. 12:1987;193-196.
39. Pennacchio L.A., Lehesjoki A.E., Stone N.E., Willour V.L., Virtaneva K., Miao J.M., et al. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science. 271:1996;1731-1734.
40. Barrett A.J., Davies M.E., Grubb A. The place of human γ-trace (cystatin C) amongst the cysteine proteinase inhibitors. Biochem. Biophys. Res. Commun. 120:1984;631-636.
41. Greenberg S.M. Cerebral amyloid angiopathy. Neurology. 51:1998;690-694.
42. Labovitz D.L., Sacco R.L. Intracerebral hemorrhage: update. Curr. Opin. Neurol. 14:2001;103-108.
43. Bornebroek M., Haan J., Maat-Schieman M.L.C., Van Duinen S.G., Roos R.A.C. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D). 1. A review of clinical, radiologic and genetic aspects. Brain Pathol. 6:1996;111-114.
44. Castano E.M., Prelli F., Soto C., Beavis R., Matsubara E., Shoji M., Frangione B. The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type - implications for the role of amyloid-beta 1-42 in Alzheimer's disease. J. Biol. Chem. 271:1996;32185-32191.
45. Maat-Schieman M.L., van Duinen S.G., Bornebroek M., Haan J., Roos R.A. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D). 2. A review of histopathological aspects. Brain Pathol. 6:1996;115-120.
46. Wei L.H., Berman Y., Castano E.M., Cadene M., Beavis R.C., Devi L., Levy E. Instability of the amyloidogenic cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. J. Biol. Chem. 273:1998;11806- 11814.
47. Crawford F.C., Freeman M.J., Schinka J.A., Abdullah L.I., Gold M., Hartman R., et al. A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. Neurology. 55:2000;763-768.
48. Levy E., Sastre M., Kumar A., Gallo G., Piccardo P., Ghetti B., Tagliavini F. Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. J. Neuropathol. Exp. Neurol. 60:2001;94-104.
49. Cohen D.H., Feiner H., Jensson O., Frangione B. Amyloid fibril in hereditary cerebral hemorrhage with amyloidosis (HCHWA) is related to the gastroentero-pancreatic, neuroendocrine protein, γ-trace. J. Expt. Med. 158:1983;623-628.
50. Jensson O., Gudmundsson G., Arnason A., Blöndal H., Petursdottir I., Thorsteinsson L., et al. Hereditary cystatin C (γ-trace) amyloid angiopathy of the CNS causing cerebral hemorrhage. Acta Neurol. Scand. 76:1987;102-114.
51. Abrahamson M. Molecular basis for amyloidosis related to hereditary brain hemorrhage. Scandin. J. Clin. Lab. Invest. 56:1996;47-56. Suppl. 226.
52. Ekiel I., Abrahamson M. Folding-related dimerization of human cystatin C. J. Biol. Chem. 271:1996;1314-1321.
53. Zerovnik E., Jerala R., KroonZitko L., Turk V., Lohner K. Characterization of the equilibrium intermediates in acid denaturation of human stefin B. Eur. J. Biochem. 245:1997;364-372.
54. Jerala R., Zerovnik E. Accessing the global minimum conformation of stefin A dimer by annealing under partially denaturing conditions. J. Mol. Biol. 291:1999;1079-1089.
55. Janowski R., Kozak M., Jankowska E., Grzonka Z., Grubb A., Abrahamson M., Jaskolski M. Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nature Struct. Biol. 8:2001;316-320.
56. Schlunegger M.P., Bennett M.J., Eisenberg D. Oligomer formation by 3D domain swapping: a model for protein assembly and misassembly. Advan. Protein Chem. 50:1997;61-122.
57. Cohen F.E., Prusiner S.B. Pathologic conformations of prion proteins. Annu. Rev. Biochem. 67:1998;793-819.
58. Liu Y., Gotte G., Libonati M., Eisenberg D. A domain-swapped RNase A dimer with implications for amyloid formation. Nature Struct. Biol. 8:2001;211-214.
59. Ding F., Dokholyan N.V., Buldyrev S.V., Stanley H.E., Shakhnovich E.I. Molecular dynamics simulation of the SH3 domain aggregation suggests a generic amyloidogenesis mechanism. J. Mol. Biol. 324:2002;851-857.
60. Knaus K.J., Morillas M., Sweietnicki W., Malone M., Surewicz W.K., Yee V.C. Crystal structure of the human prion protein reveals a mechanism for oligomerization. Nature Struct. Biol. 8:2001;770-774.
61. Silow M., Tan Y.J., Fersht A.R., Oliveberg M. Formation of short-lived protein aggregates directly from the coil in two-state folding. Biochemistry. 38:1999;13006-13012.
62. Ekiel I., Abrahamson M., Fulton D.B., Lindahl P., Storer A.C., Levadoux W., et al. NMR structural studies of human cystatin C dimers and monomers. J. Mol. Biol. 271:1997;266-277.
63. Hayes M.V., Sessions R.B., Brady R.L., Clarke A.R. Engineered assembly of intertwined oligomers of an immunoglobulin chain. J. Mol. Biol. 285:1999;1857-1867.
64. Libonati M., Bertoldi M., Sorrentino S. The activity on double-stranded RNA of aggregates of ribonuclease A higher than dimers increases as a function of the size of the aggregates. Biochem. J. 318:1996;287-290.
65. Dieckmann T., Mitschang L., Hofmann M., Kos J., Turk V., Auerswald E.A., et al. The structures of native phosphorylated chicken cystatin and of a recombinant unphosphorylated in solution. J. Mol. Biol. 234:1993;1048-1059.
66. Engh R.A., Dieckmann T., Bode W., Auerswald E.A., Turk V., Huber R., Oschkinat H. Conformational variability of chicken cystatin: comparison of structures determined by X-ray diffraction and NMR spectroscopy. J. Mol. Biol. 234:1993;1060-1069.
67. Parker M.J., Lorch M., Sessions R.B., Clarke A.R. Thermodynamic properties of transient intermediates and transition states in the folding of two contrasting protein structures. Biochemistry. 37:1998;2538-2545.
68. Zurdo J., Guijarro J.I., Jimenez J.L., Saibil H.R., Dobson C.R. Dependence on solution conditions of aggregation and amyloid formation by an SH3 domain. J. Mol. Biol. 311:2001;325-340.
69. Conway K.A., Harper J.D., Lansbury P.T. Jr. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry. 39:2000;2552-2563.
70. Staniforth R.A., Dean J.L.E., Zhong Q., Clarke A.R., Zerovnik E., Waltho J.P. The major transition state in protein folding need not involve the immobilization of side chains. Proc. Natl Acad. Sci. USA. 97:2000;5790-5795.
71. Newcomer M.E. Trading places. Nature Struct. Biol. 8:2001;282-284.
72. Martin J.R., Craven C.J., Jerala R., Kroon-Zitko L., Zerovnik E., Turk V., Waltho J.P. The three-dimensional solution structure of human stefin A. J. Mol. Biol. 246:1995;331-343.
73. Calero M., Pawlick M., Soto C., Castaño E.M., Sigurdsson E.M., Kumar A., et al. Distinct properties of wild-type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. J. Neurochem. 77:2001;628-637.
74. Zerovnik E., Pompe-Novak M., Skarabot M., Ravnikar M., Musevi I., Turk V. Human stefin B readily forms amyloid fibrils in vitro. Biochim. Biophys. Acta. 1594:2001;1-5.
75. Baskakov I.V., Legname G., Baldwin M.A., Prusiner S.B., Cohen F.E. Pathway complexity of prion protein assembly into amyloid. J. Biol. Chem. 277:2002;21140-21148.
76. Ding T.T., Lee S.-J., Rochet J.-C., Lansbury P.T. Jr. Annular α-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry. 41:2002;10209-10217.
77. Anastasi A., Brown M.A., Kembhavi A.A., Nicklin M.J.H., Sayers C.A., Sunter D.C., Barrett A.J. Cystatin, a protein inhibitor of cysteine proteinases - improved purification from egg white. Biochem. J. 211:1983;129-138.
78. Klunk W.E., Jacob R.F., Mason R.P. Quantifying amyloid by Congo red spectral shift assay. Methods Enzymol. 309:1999;285-305.